CalciMedica Announces Presentations at Upcoming Medical Meetings

PR Newswire

2024-11-21

Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2485175596"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485175596\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485175596?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MeD0tk6AKrx2QxGxO5XuHA--~B/aD03ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae","is_english":true,"pubTime":"2024-11-21 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485175596","market":"us","top_or_hot":-1,"title":"CalciMedica Announces Presentations at Upcoming Medical Meetings","media":"PR Newswire","content":"<div>\n<p>Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting\nPoster presentation on ...</p>\n\n<a href=\"https://finance.yahoo.com/news/calcimedica-announces-presentations-upcoming-medical-210500876.html\">網頁鏈接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CalciMedica Announces Presentations at Upcoming Medical Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalciMedica Announces Presentations at Upcoming Medical Meetings\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">PR Newswire</strong><span class=\"h-time small\">2024-11-21 05:05</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting\nPoster presentation on ...</p>\n\n<a href=\"https://finance.yahoo.com/news/calcimedica-announces-presentations-upcoming-medical-210500876.html\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/calcimedica-announces-presentations-upcoming-medical-210500876.html\">PR Newswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://finance.yahoo.com/news/calcimedica-announces-presentations-upcoming-medical-210500876.html","article_id":"2485175596","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MeD0tk6AKrx2QxGxO5XuHA--~B/aD03ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/calcimedica-announces-presentations-upcoming-medical-210500876.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485175596","pubTimestamp":1732136700,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Prof. Robert Sutton todeliver plenary presentation on Phase 2b CARPO trial of Auxora in Acute Pancreatitis at American Pancreatic Association  2024 Annual Meeting. Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine  2024 Meeting. LA JOLLA, Calif., Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc.  , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium  channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at the American Pancreatic Association  2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine  2024 Meeting being held December 8-13 in Maui, HI.Presentation Title: Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS. Presenter:Prof. Robert Sutton, B.A. , M.B., B.S., D.P","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AP":"安博科-匹兹堡","BK4588":"碎股","CALC":"CALCIMEDICA","EIM":"Eaton Vance Municipal Bond Fun","BK4213":"石油与天然气的勘探与生产","APA":"阿帕契","BK4585":"ETF&股票定投概念","BK4006":"钢铁"},"translate_title":"CalciMedica宣布在即将举行的医学会议上发表演讲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AP":1,"APA":1,"CALC":0.9,"EIM":1},"content_text":"Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting\nPoster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting \nLA JOLLA, Calif., Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. (\"CalciMedica\") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at  the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.\n\n  \n\nDetails for the presentations are as follows:\nPlenary Presentation at APA 2024 Annual Meeting\nPresentation Title: Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS\nPresenter: Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust\nSession Title: Abstract Session 2 – Pancreatitis \nSession Date and Time: Tuesday, December 10, 8:00-9:30 a.m. HST\nPoster Presentation at EIM 2024 Meeting\nPresentation Title: A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS)- CARPO (NCT0468106)\nThe presentation and poster will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at https://ir.calcimedica.com/news-events/medical-events-publications.\nAbout CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.\nForward-Looking StatementsThis communication contains forward-looking statements which include, but are not limited to,  CalciMedica's ongoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption \"Risk Factors\" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023,  and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.\nCalciMedica Contact:\nInvestors and MediaArgot PartnersSarah Sutton/Kevin Murphycalcimedica@argotpartners.com(212) 600-1902\n View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-upcoming-medical-meetings-302312062.html\nSOURCE CalciMedica, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}